
FORM D

Notice of Exempt Offering of Securities

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C.



1. Issuer's Identity		
CIK (Filer ID Number)	Previous Name(s) 🔲 None	Entity Type
0001736243	Ampex Pharmaceuticals, LLC	C Corporation
Name of Issuer		C Limited Partnership
Acurx Pharmaceuticals, LLC		Limited Liability Company
Jurisdiction of Incorporation/Organization		C General Partnership
DELAWARE		C Business Trust
Year of Incorporation/Organizat	ion	C Other
O Over Five Years Ago		L
 Within Last Five Years (Specify Year) 	2017	

C Yet to Be Formed

 2. Principal Place of Business and Contact Information

 Name of Issuer

 Acurx Pharmaceuticals, LLC

 Street Address 1

 Street Address 2

 [22 CAMELOT COURT

 City
 State/Province/Country

 ZIP/Postal Code
 Phone No. of Issuer

 [WHITE PLAINS]
 [NEW YORK

3. Related Persons

Last Name		First Name		Middle Name		
Luci		David		P.		
Street Address 1			s	treet Address 2	- <u>-</u>	
22 Camelot Court						
City State/Province/		State/Province/C	Count	ry	ZIP/Pos	stal Code
White Plains		NEW YORK		10603		
<u>.</u>						
Relationship:	Execut	ive Officer	•	Director		Promoter
Last Name		First Name			Middle	Name
DeLuccia		Robert			J.	
Street Address 1			S	treet Address 2		
22 Camelot Court						
City		State/Province/C	Count	ry	ZIP/Pos	stal Code
White Plains		NEW YORK			10603	
Relationship:	Execut	ive Officer	•	Director		Promoter

Clarification of Response (if Necessary)
-----------------------------	---------------

Last Name	First Name	Middle Name		
Shawah	Robert	G.		
Street Address 1	Street Address 2			
22 Camelot Court				
City	State/Province/Country	ZIP/Postal Code		
White Plains	NEW YORK	10603		
Relationship: Execut	tive Officer Director	Promoter		
Clarification of Response (if Necessary)				
	·			

4. Industry Group

- C Agriculture
 - **Banking & Financial Services**
 - C Commercial Banking
 - C Insurance
 - C Investing
 - C Investment Banking
 - C Pooled Investment Fund
 - Other Banking & Financial

C Business Services

Energy

- C Coal Mining
- C Electric Utilities
- C Energy Conservation
- C Environmental Services
- C Oil & Gas

5. Issuer Size Revenue Range

No Revenues

\$1 - \$1,000,000

\$1,000,001 - \$5,000,000

\$5,000,001 - \$25,000,000

Over \$100,000,000

Decline to Disclose

Not Applicable

\$25,000,001 - \$100,000,000

C

C

C

C

C

C

 \odot

C

C Other Energy

- BiotechnologyHealth Insurance
- C Hospitals & Physicians

Health Care

C Manufacturing

Real Estate

0

0

C Commercial

Construction

REITS & Finance

- C Pharmaceuticals
- C Other Health Care
- C Other Technology

Travel

C Retailing

C Restaurants

Technology

C Computers

C Airlines & Airports

C Telecommunications

- C Lodging & Conventions
- C Tourism & Travel Services
- C Other Travel
- C Other
- C ResidentialC Other Real Estate

Aggregate Net Asset Value Range

- O No Aggregate Net Asset Value
- S1 \$5,000,000

C

- \$5,000,001 \$25,000,000
- C \$25,000,001 \$50,000,000
- C \$50,000,001 \$100,000,000
- Over \$100,000,000
- C Decline to Disclose
- C Not Applicable

6. Federal Exemption(s) and Exclusion(s) Claimed (select all that apply) Rule 504(b)(1) (not (i), (ii) or (iii)) Rule 505

Rule 504 (b)(1)(i)	Rule 506(b)				
Rule 504 (b)(1)(ii)	Rule 506(c)				
Rule 504 (b)(1)(iii)	Securities Act Section 4(a)(5)				
	Investment Company Act Section 3(c)				
<u></u>					
7. Type of Filing					
7. Type of Filing					

Amendment

8. Duration of Offering

Does the Issuer intend this offering to last more than one year?

 9. Type(s) of Securities Offered (select all that apply)

 □
 Pooled Investment Fund Interests
 Image: Equity

 □
 Tenant-in-Common Securities
 □
 Debt

 □
 Mineral Property Securities
 Image: Option, Warrant or Other Right to Acquire Another Security

 Security to be Acquired Upon Exercise of Option, Warrant or Other Right to Acquire Security
 □
 Other (describe) Other (describe)

C Yes © No

10. Business Combination Transaction

Is this offering being made in connection with a business combination C Yes No transaction, such as a merger, acquisition or exchange offer?

Clarification of Response (if Necessary)

11. Minimum Investment		
Minimum investment accepted from any outside	\$ 0	USD

12. Sales Compensation	
Recipient	Recipient CRD Number
(Associated) Broker or Dealer 📃 None	(Associated) Broker or Dealer CRD 🔲 None
Street Address 1	Street Address 2
City St	ate/Province/Country ZIP/Postal Code
State(s) of Solicitation	□ All States

Total Offering Amount \$ USD [] Indefinite
Total Amount Sold \$ 3811500 USD
Total Remaining to be
Sold
Clarification of Response (if Necessary)
14. Investors
Select if securities in the offering have been or may be sold to persons who do not qualify as accredited investors, Number of such non-accredited investors who already have invested in the offering
Regardless of whether securities in the offering have been or may be sold to persons who do not qualify as accredited investors, enter the total number of investors who already have invested in the offering:
15. Sales Commissions & Finders' Fees Expenses
Provide separately the amounts of sales commissions and finders' fees expenses, if any. If the amount of an expenditure is not known, provide an estimate and check the box next to the amount.
Sales Commissions \$ 0 USD Estimate
Finders' Fees \$ 0 USD Estimate
Clarification of Response (if Necessary)
,
16. Use of Proceeds
Provide the amount of the gross proceeds of the offering that has been or is proposed to be used for payments to any of the persons required to be named as executive officers, directors or promoters in response to Item 3 above. If the amount is unknown, provide an estimate and check the box next to the amount.
\$ USD Estimate
Clarification of Response (if Necessary)
Signature and Submission
<u> </u>
Please verify the information you have entered and review the Terms of Submission below before signing and clicking SUBMIT below to file this notice.
Terms of Submission
 In submitting this notice, each Issuer named above is: Notifying the SEC and/or each State in which this notice is filed of the offering of securities described and undertaking to furnish them, upon written request, the information furnished to
 offerees. Irrevocably appointing each of the Secretary of the SEC and, the Securities Administrator or other legally designated officer of the State in which the Issuer maintains its principal place of business and any State in which this notice is filed, as its agents for service of process, and agreeing that these persons may accept service on its behalf, of any notice, process or pleading, and further agreeing that such service may be made by registered or certified mail, in any Federal or state action, administrative proceeding, or arbitration brought against it in any place subject to the jurisdiction of the United States, if the action, proceeding or arbitration (a) arises out of any activity in connection with the offering of securities that is the subject of this notice, and (b) is founded, directly or indirectly, upon the provisions of: (i) the Securities Act of 1933, the Securities Exchange Act of 1934, the Trust Indenture Act of 1939, the Investment Company Act of 1940, or the Investment Advisers Act of 1940, or any rule or regulation under any of these statutes, or (ii) the laws of the State in which the issuer maintains its principal place of business or any State in which this notice is filed.

• Certifying that, if the issuer is claiming a Regulation D exemption for the offering, the issuer is not disqualified from relying on Regulation D for one of the reasons stated in Rule 505(b)(2)(iii) or Rule 506(d).

Each Issuer identified above has read this notice, knows the contents to be true, and has duly caused this notice to be signed on its behalf by the undersigned duly authorized person.

For signature, type in the signer's name or other letters or characters adopted or authorized as the signer's signature.

Issuer	Signature	Name of Signer	Title	Date
Acurx Pharmaceuticals, LLC	/s/ David P. Luci	David P Luci	Co-Founder and Managing Partner	2018-10-30